Cargando…

Apatinib Combined with Irinotecan in the Treatment of Advanced Small-Cell Esophageal Carcinoma: A Case Report

Chemotherapy is the mainstay of treatment for advanced small cell esophageal carcinoma (SCEC) characterized by poor prognosis. Preclinical studies demonstrated that apatinib has the potential to enhance the efficacy of conventional chemotherapeutic drugs and reverse multidrug resistance (MDR). This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Longhua, Zou, Xiaofang, Gu, Yinfang, Yi, Lilan, Zhao, Jingjing, Wu, Guowu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987322/ https://www.ncbi.nlm.nih.gov/pubmed/33776448 http://dx.doi.org/10.2147/OTT.S295067

Ejemplares similares

Clinical Significance and Immune Landscape of Recurrence-Associated Ferroptosis Signature in Early-Stage Lung Adenocarcinoma
por: Yi, Lilan, et al.
Publicado: (2022)

Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis
por: Gu, Yinfang, et al.
Publicado: (2020)

Comprehensive Analysis of the PD-L1 and Immune Infiltrates of m(6)A RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma
por: Yi, Lilan, et al.
Publicado: (2020)

Optimal timing of antiviral therapy for patients with malignant tumor who presented with hepatitis B reactivation during chemotherapy and/or immunosuppressive therapy
por: Zou, Xiaofang, et al.
Publicado: (2020)

Phase 1 dose-escalation study of apatinib and irinotecan in esophageal squamous cell carcinoma patients
por: Jia, Jun, et al.
Publicado: (2021)

The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients
por: Wu, Guowu, et al.
Publicado: (2022)

Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma
por: Zhao, Jian, et al.
Publicado: (2019)

Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma
por: Li, Jianqiang, et al.
Publicado: (2017)

Clinical efficacy and survival analysis of apatinib combined with docetaxel in advanced esophageal cancer
por: Li, Jing, et al.
Publicado: (2019)

S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

Fatal hemoptysis in patients with advanced esophageal cancer treated with apatinib
por: Wang, Wei, et al.
Publicado: (2018)

Apatinib is effective for treatment of advanced hepatocellular carcinoma
por: Kong, Yinlong, et al.
Publicado: (2017)

Apatinib as an alternative therapy for advanced hepatocellular carcinoma
por: Zhang, Xi-Hao, et al.
Publicado: (2020)

Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma
por: Zhang, Bo, et al.
Publicado: (2020)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma
por: Liu, Yun, et al.
Publicado: (2021)

Advanced Hepatocellular Carcinoma With Hepatic Arterioportal Shunts: Combination Treatment of Transarterial Chemoembolization With Apatinib
por: Sun, Tao, et al.
Publicado: (2020)

A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
por: Yang, Qing, et al.
Publicado: (2023)

Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: Ye, Wei, et al.
Publicado: (2022)

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
por: Kim, Miso, et al.
Publicado: (2017)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma
por: Hu, Lijun, et al.
Publicado: (2020)

Apatinib combined with concurrent chemoradiotherapy in patients with subglottic small cell carcinoma: a case report
por: Chen, Man, et al.
Publicado: (2021)

Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway
por: Wei, Bin, et al.
Publicado: (2020)

Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kan, Xuefeng, et al.
Publicado: (2020)

Tislelizumab combined with apatinib in the treatment of advanced renal clear cell carcinoma: a case report
por: Qu, Fanjie, et al.
Publicado: (2021)

Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Cui, Yu-jie, et al.
Publicado: (2021)

Retracted: Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy
por: Chi, Dongmei, et al.
Publicado: (2021)

Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report
por: Liang, Li-Jun, et al.
Publicado: (2018)

PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study
por: Wei, Qing, et al.
Publicado: (2020)

Salvage treatment with apatinib for advanced non-small-cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2017)

Pembrolizumab combined with paclitaxel and platinum as induction therapy for locally advanced esophageal squamous cell carcinoma: a retrospective, single-center, three-arm study
por: Lin, Wenbao, et al.
Publicado: (2022)

Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma
por: Gu, Xiaoying, et al.
Publicado: (2022)

Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021)

Safety Analysis of Apatinib Combined with Chemotherapy in the Treatment of Advanced Gastric Carcinoma: A Randomised Controlled Trial
por: Yuan, Min, et al.
Publicado: (2021)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
por: Ni, Jun, et al.
Publicado: (2023)

Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
por: Qu, Jinglei, et al.
Publicado: (2023)

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
por: Negoro, S, et al.
Publicado: (2003)

Apatinib-treated advanced medullary thyroid carcinoma: a case report
por: Chen, Kan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8pa4on30q8s8ifofbkt6lntbqg